Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ME2 | P23368 | 3/20 | 0.60 |
| ▸ | ME1 | P48163 | 3/20 | 0.60 |
| ▸ | ME3 | Q16798 | 3/20 | 0.60 |
| ▸ | GRM5 | P41594 | 4/20 | 0.59 |
| ▸ | MAPT | P10636 | 9/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2312575 | 0.88 | ME2 (0.64) | ME2ME1ME3GRM5MAPT | |
| SCHEMBL12916426 | 0.88 | MAPT (0.62) | ME2ME1ME3MAPTKDM4E | |
| Hydrochloric Acid SCHEMBL2309495 | 0.86 | ME2 (0.58) | ME2ME1ME3GRM5MAPT | |
| SCHEMBL945380 | 0.84 | ME2 (0.61) | ME2ME1ME3MAPTKDM4E | |
| SCHEMBL12206749 | 0.84 | MAPT (0.77) | ME2ME1ME3GRM5MAPT | |
| SCHEMBL12916432 | 0.84 | MAPK1 (0.59) | ME2ME1ME3GRM5MAPT | |
| SCHEMBL23259338 | 0.83 | ME2 (0.59) | ME2ME1ME3GRM5MAPT | |
| SCHEMBL2307404 | 0.83 | MAPK1 (0.62) | ME2ME1ME3GRM5MAPT | |
| SCHEMBL3299369 | 0.82 | MAPT (0.70) | GRM5MAPTNPC1GAANPSR1 | |
| SCHEMBL28788691 | 0.81 | MAPT (0.55) | ME2ME1ME3GRM5MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2234973-B1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INT BV (NL) | 2014-07-02 | — | — | EP | disclosed |
| EP-2234973-B1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INT BV (NL) | 2014-07-02 | — | — | EP | disclosed |
| US-8569495-B2 | Anthelmintic agents and their use | INTERVET INTERNATIONAL B.V. (NL) | 2013-10-29 | — | — | US | disclosed |
| US-8569495-B2 | Anthelmintic agents and their use | INTERVET INTERNATIONAL B.V. (NL) | 2013-10-29 | — | — | US | disclosed |
| US-8569495-B2 | Anthelmintic agents and their use | INTERVET INTERNATIONAL B.V. (NL) | 2013-10-29 | — | — | US | disclosed |
| CN-101896459-B | Anthelmintic and its use | INTERVET INT BV | 2013-07-24 | — | — | CN | disclosed |
| US-20110021506-A1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INTERNATIONAL B.V. (NL) | 2011-01-27 | — | — | US | disclosed |
| US-20110021506-A1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INTERNATIONAL B.V. (NL) | 2011-01-27 | — | — | US | disclosed |
| US-20110021506-A1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INTERNATIONAL B.V. (NL) | 2011-01-27 | — | — | US | disclosed |
| CN-101896459-A | Anthelmintic and its use | INTERVET INT BV | 2010-11-24 | — | — | CN | disclosed |
| EP-2234973-A1 | ANTHELMINTIC AGENTS AND THEIR USE | Intervet International B.V. (NL) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009077527-A1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INTERNATIONAL B.V. (NL) | 2009-06-25 | — | — | WO | disclosed |
| WO-2009077527-A1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INTERNATIONAL B.V. (NL) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021506-A1 | ANTHELMINTIC AGENTS AND THEIR USE | ACHE, ABCB11, MPO | ME2 472/4885ME1 411/4885ME3 291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.